ReviewRisk factors and drugs in the treatment of hypertensionRobertson, J Ian S.1Author Information 1Department of Medicine, Prince of Wales Hospital, Chinese University, Hong Kong. Requests for reprints to Dr J.I.S. Robertson, Elmbank, Manse Road, Bowling, Glasgow G60 5AA, UK. Journal of Hypertension: Volume 15 - Issue 1 - p S43-S46 Buy Abstract Background A wide range of drug classes, frequently including centrally acting agents, has been used in clinical trials in hypertension which have shown benefit. Although therapy has clearly limited the complications of hypertension, further improvement is needed, especially concerning coronary artery disease. Perspectives Future interest therefore centres on drugs that do not worsen diabetes mellitus, do not cause dyslipidaemia, or induce potassium loss, while not provoking drowsiness, depression, other troublesome side-effects, or being associated with rebound hypertension when stopped. The centrally acting imidazoline agonists merit detailed study in this regard. © Lippincott-Raven Publishers.